0001193125-26-210292
SEC filingOperating losses widened to -$43.8M as R&D expenses increased primarily due to the Phase 3 LUCIDITY trial for avexitide and other programs, while net loss grew to -$41.3M but EPS improved to -$0.37 from share count changes, with cash burn moderating to -$36.9M.
Net income followed a similar trajectory, deepening to -$41.3 million from -$35.9 million, representing a 15.0% wider loss. However, diluted EPS showed improvement at -$0.37 compared to -$0.42 year-over-year, a 11.9% positive shift attributable to changes in the weighted average shares outstanding. This dynamic highlights how equity issuances or other share-related factors can mitigate per-share impacts amid growing absolute losses, providing a nuanced view for investors tracking dilution effects.
Selling, general, and administrative expenses trended higher, with consulting and professional services increasing due to commercial and marketing activities preparing for a potential avexitide launch, if approved, plus elevated general legal spend. Management notes this pre-commercialization ramp, expecting SG&A to continue rising with headcount growth, pipeline advancement, and near-term regulatory preparations. R&D expenses are also projected to increase with planned clinical activities.